Pharmaceutical Outsourcing Company Focus: A Russell Publishing Publication

COMPANY DESCRIPTION

AMRI (founded in 1991 as Albany Molecular Research, Inc.) provides scientific services, products and technologies that improve quality of life while delivering excellence, value and maximum return. Its business is comprised of a fee-for-service contract services platform encompassing drug discovery, development
and manufacturing, and a separate, strategic technology division that includes proprietary technology investments, internal drug discovery and niche generic active pharmaceutical ingredient product development.

COMPANY BACKGROUND

# of employees 1,300 +
Annual Revenues $229 million

Key Personnel

Key personnel include:
• Thomas E. D’Ambra, Ph.D. - Chairman and Chief
Executive Officer
• Mark T. Frost - Chief Financial Officer
• Steve Jennings - Senior Vice President, Sales, Marketing,
Business Development
• Steven R. Hagen, Ph.D. - Vice President, Pharmaceutical
Development & Manufacturing
• Michael P. Trova, Ph.D. - Senior Vice President, Chemistry
• Bruce J. Sargent, Ph.D. - Vice President, Discovery R&D

AMRI (NASDAQ: AMRI) celebrates almost twenty years as a premier contract

FACILITIES

With locations throughout the United States, Singapore, Hungary and Asia, AMRI is
uniquely positioned to provide customized solutions utilizing the company’s broad range of services, technologies, locations and cost models.

SERVICES & CAPABILITIES

AMRI provides a broad spectrum of integrated chemistry and biology services backed by a highly experienced and educated scientific staff. Its tightly integrated services can be accessed independently or as a full drug discovery, development, and manufacturing platform.

At the earliest stages of drug discovery, AMRI helps customers identify and optimize biologically active compounds using both natural product-based and synthetic chemical libraries, along with in vitro biology capabilities. Once a lead compound is identified, AMRI provides medicinal chemistry and lead optimization coupled with technologies in metabolism and biotransformation.

AMRI provides a variety of key development services to help move compounds into clinical trials including chemical process R&D, preformulation, formulation development, analytical development, separation sciences and bioanalytical services. Additionally, AMRI can scale-up compounds for preclinical testing, as well as develop new synthetic routes to target compounds.

AMRI’s large scale facilities provide manufacturing of active pharmaceutical ingredients (API), advanced intermediates, and a number of high quality generic APIs. Its U.S.-based commercial cGMP facility manufactures a number of customer compounds for both clinical trials and commercial products and provides specialized capabilities in the areas of high potency and controlled substance manufacturing. Production facilities in Asia provide a reliable and cost-effective supply chain of non-GMP intermediates for the company’s U.S. large scale facility.